Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56% reduction in ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...